Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.19B

Market cap28.19B

Price-Earnings ratio

20.86

Price-Earnings ratio20.86

Dividend yield

—

Dividend yield—

Average volume

1.11M

Average volume1.11M

High today

$195.47

High today$195.47

Low today

$180.18

Low today$180.18

Open price

$183.16

Open price$183.16

Volume

1.08M

Volume1.08M

52 Week high

$202.41

52 Week high$202.41

52 Week low

$115.25

52 Week low$115.25

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $192.06. The company's market cap stands at 28.19B, with a P/E ratio of 20.86.

As of 2026-04-29, Biogen(BIIB) stock has fluctuated between $180.18 and $195.47. The current price stands at $192.06, placing the stock +6.6% above today's low and -1.7% off the high.

The Biogen(BIIB)'s current trading volume is 1.08M, compared to an average daily volume of 1.11M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $115.25.

BIIB News

Nasdaq 1h

Biogen Q1 2026 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

The Wall Street Journal 6h

Biogen Lowers 2026 Earnings Outlook

Biogen lowered its earnings guidance and projected weaker revenue for 2026. BRIAN SNYDER / REUTERS Biogen BIIB 1.50 %increase; green up pointing triangle lower...

TipRanks 7h

Biogen lowers FY26 adjusted EPS view to $14.25-$15.25, consensus $15.55

Full year 2026 total revenue expected to decline by a mid-single digit percentage versus full year 2025. Full year 2026 Non-GAAP diluted EPS is now expected to...

Analyst ratings

53%

of 38 ratings

Buy

52.6%

Hold

42.1%

Sell

5.3%

More BIIB News

Simply Wall St 1d

Is Biogen Still Attractive After Recent Share Price Rebound And DCF Upside Estimate

For investors considering whether Biogen's share price reflects its underlying value, the recent mix of long term gains and shorter term pullbacks makes the val...

Nasdaq 5d

Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen BIIB will report first-quarter 2026 results on April 29, before market open. In the last reported quarter, the company's earnings beat expectations by 23...

Simply Wall St 6d

Biogen Gains China Felzartamab Rights As Valuation Gap Draws Attention

Biogen (NasdaqGS:BIIB) has acquired exclusive rights to felzartamab in the Greater China Region from TJ Biopharma. The deal consolidates global rights to felza...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.